Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-08-17. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0001193125-26-354313
acquired disposedA
codeM
direct or indirectD
form4
is derivativefalse
issuer name4D Molecular Therapeutics, Inc.
labelExercise of derivative
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0001193125-26-354313",
"acquired_disposed": "A",
"code": "M",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "4D Molecular Therapeutics, Inc.",
"label": "Exercise of derivative",
"person_name": "Bizily Scott",
"price": 4.14,
"role": "Chief Legal Officer",
"security": "Common Stock",
"shares": 1635,
"shares_owned_after": 10252,
"source_path": "edgar/data/1650648/0001193125-26-354313.txt",
"ticker": "FDMT",
"transaction_date": "2026-08-17",
"value": 6768.9
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.